Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2016-08-03
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of trebananib when given
together with or without low-dose cytarabine in treating patients with acute myeloid leukemia
(AML). Trebananib may stop the growth of AML by blocking blood flow to the cancer. Drugs used
in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving trebananib
together with cytarabine may be an effective treatment for patients with AML.